Low-dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as an Alternative Therapy for Ovarian Cancer in an Octogenarian Patient

被引:0
作者
Giger-Pabst, Urs [1 ]
Solass, Wiebke [3 ]
Buerkle, Bernd [2 ]
Reymond, Marc-Andre [1 ]
Tempfer, Clemens B. [2 ]
机构
[1] Ruhr Univ Bochum, Dept Surg, Bochum, Germany
[2] Ruhr Univ Bochum, Dept Obstet & Gynecol, Bochum, Germany
[3] Hannover Med Sch, Inst Pathol, Hannover, Germany
关键词
Ovarian cancer; quality of life; antineoplastic agents; adverse effects; intraperitoneal chemotherapy; peritoneal carcinomatosis; octogenarian; high pressure; QUALITY-OF-LIFE; PERITONEAL CARCINOMATOSIS; FEASIBILITY; CISPLATIN; WOMEN;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Octogenarians with ovarian cancer limited to the abdomen may not be willing or able to undergo systemic chemotherapy. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin is a form of intra-abdominal chemotherapy which can be applied repeatedly and potentially prevents from the systemic side-effects of chemotherapy. Case Report: We present the case of an 84-year-old woman with laparoscopically and histologically confirmed ovarian cancer who refused to undergo systemic chemotherapy. She was treated with eight courses q 28-104 days of low-dose PIPAC with cisplatin at 7.5 mg/m(2) and doxorubicin at 1.5 mg/m(2) at 12 mmHg and 37 degrees C for 30 min. Objective tumor response was noted, defined as tumor regression on histology, and stable disease noted by peritoneal carcinomatosis index on repeated video-laparoscopy and abdominal computed tomographic scan. The treatment was well-tolerated with no Common Terminology Criteria for Adverse Events (CTCAE) CTCAE >2. With a follow-up of 15 months, the patient is alive and clinically stable. The quality of life measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 demonstrated improvement over 5-6 months (global physical score, global health score, global quality of live) without cumulative increase of gastrointestinal toxicity. Conclusion: Low-dose PIPAC is a new form of intra peritoneal chemotherapy which may be applied repeatedly in octogenarian patients. PIPAC may be an alternative and well-tolerated treatment for selected octogenarian patients with ovarian cancer limited to the abdomen who cannot be treated with systemic chemotherapy.
引用
收藏
页码:2309 / 2314
页数:6
相关论文
共 50 条
  • [41] Establishment of a rat ovarian peritoneal metastasis model to study pressurized intraperitoneal aerosol chemotherapy (PIPAC)
    Leen Van de Sande
    Wouter Willaert
    Sarah Cosyns
    Kaat De Clercq
    Molood Shariati
    Katrien Remaut
    Wim Ceelen
    BMC Cancer, 19
  • [42] Establishment of a rat ovarian peritoneal metastasis model to study pressurized intraperitoneal aerosol chemotherapy (PIPAC)
    Van de Sande, Leen
    Willaert, Wouter
    Cosyns, Sarah
    De Clercq, Kaat
    Shariati, Molood
    Remaut, Katrien
    Ceelen, Wim
    BMC CANCER, 2019, 19 (1)
  • [43] Occupational exposure to cisplatin/oxaliplatin during Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)?
    Ametsbichler, Paul
    Boehlandt, Antje
    Nowak, Dennis
    Schierl, Rudolf
    EJSO, 2018, 44 (11): : 1793 - 1799
  • [44] Comparison between microcatheter and nebulizer for generating Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
    Laura Toussaint
    Yaroslav Sautkin
    Barbara Illing
    Frank-Jürgen Weinreich
    Giorgi Nadiradze
    Alfred Königsrainer
    Dörte Wichmann
    Surgical Endoscopy, 2021, 35 : 1636 - 1643
  • [45] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study
    Jansen-Winkeln, B.
    Eberth, J.
    Moulla, Y.
    Mehdorn, M.
    Niebisch, S.
    Schierle, K.
    Blaeker, H.
    Lordick, F.
    Gockel, I.
    Thieme, R.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1331 - 1341
  • [46] Radiologist Checklist for Selecting Patients to Undergo PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy)
    Rodolfino, Elena
    Di Marco, Margo'
    Ilot, Alessia
    Iezzi, Roberto
    Gui, Benedetta
    Avesani, Giacomo
    Panico, Camilla
    Strippoli, Antonia
    Di Giorgio, Andrea
    Pacelli, Fabio
    Manfredi, Riccardo
    LIFE-BASEL, 2021, 11 (09):
  • [47] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report
    Tempfer, Clemens B.
    Solass, Wiebke
    Buerkle, Bernd
    Reymondc, Marc-Andre
    GYNECOLOGIC ONCOLOGY REPORTS, 2014, 10 : 32 - 35
  • [48] Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model
    Khosrawipour, Veria
    Khosrawipour, Tanja
    Kern, Alexander Jens Peter
    Osma, Aras
    Kabakci, Burak
    Diaz-Carballo, David
    Foerster, Eckart
    Zieren, Juergen
    Fakhrian, Khashayar
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (11) : 2275 - 2280
  • [49] Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center
    Ceribelli, C.
    Debs, T.
    Chevallier, A.
    Piche, M. A.
    Bereder, J. M.
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2020, 34 (06): : 2803 - 2806
  • [50] Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center
    C. Ceribelli
    T. Debs
    A. Chevallier
    M. A. Piche
    J. M. Bereder
    Surgical Endoscopy, 2020, 34 : 2803 - 2806